The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Reduced p62 levels are associated with the induction of the cancer-associated fibroblast (CAF) phenotype, which promotes tumorigenesis in vitro and in vivo through inflammation and metabolic reprogramming. However, how p62 is downregulated in the stroma fibroblasts by tumor cells to drive CAF activation is an unresolved central issue in the field. Here we show that tumor-secreted lactate downregulates p62 transcriptionally through a mechanism involving reduction of the NAD + /NADH ratio, which impairs poly(ADP-ribose)-polymerase 1 (PARP-1) activity. PARP-1 inhibition blocks the poly(ADP-ribosyl)ation of the AP-1 transcription factors, c-FOS and c-JUN, which is an obligate step for p62 downregulation. Importantly, restoring p62 levels in CAFs by NAD + renders CAFs less active. PARP inhibitors, such as olaparib, mimick lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo , which suggests that therapies using olaparib would benefit from strategies aimed at inhibiting CAF activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 1×
“…many functions through the secretion of stromal growth factors and inflammatory mediators, by reprogramming their metabolism to provide nutrients and survival factors, and by remodeling the extracellular matrix (ECM) (Hanahan and Weinberg, 2011; Kasashima et al., 2020; Sahai et al., 2020).”
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00313-x · Cited by 1,617 · cited 9×
“NAD + is a cofactor for three types of transcriptional and post-translational modulators, including sirtuins (SIRT1 through SIRT7), cyclic ADP-ribose synthases (CD38 and CD157), and PARPs (PARP-1/2) (Covarrubias et al., 2021).”
InfluentialThe Science and Translation of Lactate Shuttle Theory
Brooks, G. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.008 · Cited by 1,486 · cited 9×
“Most tumor cells can engage in secretion and utilization of lactate depending on the context and extracellular microenvironment (Brooks, 2018).”
InfluentialJain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · cited 2×
“PARP-1 is the major isoform of the PARP enzyme family and, like the other PARPs, its PARylation activity impacts multiple biological processes with a main dual function in DDR and transcriptional regulation (Feng et al., 2015; Gibson and Kraus, 2012).”
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792 · cited 1×
“…successfully exploited in BRCA1/2-deficient breast and ovarian cancers (Sonnenblick et al., 2015), and recently olaparib has been approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients with DDR gene mutations (de Bono et al., 2020; Hussain et al., 2020).”
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744 · cited 1×
“…synergistic crosstalk promotes malignancy and is believed to negatively impact cancer treatment by promoting the accumulation of “persisting” or “resistant” tumor cells, which limit therapy efficacy and promote resistance (Bluemn et al., 2017; Linares et al., 2017; Zhang et al., 2020).”
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743 · cited 1×
“…the creation of synthetic lethality in combination with genetic defects in homologous recombination-mediated repair (Farmer et al., 2005; Lord and Ashworth, 2017; McCabe et al., 2006), which are the basis for the treatment of patients with BRCA1-and BRCA2-associated cancers (Mateo et al., 2019).”
Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03421-7 · Cited by 588
Cited by
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
Lactate as a myokine and exerkine: drivers and signals of physiology and metabolism
Brooks, G. A., Osmond, A. D., Arevalo, J. A., Duong, J. J., Curl, C. C., Moreno-Santillan, D. D., & Leija, R. G. (2023) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00497.2022 · Cited by 171
Kitamura, F., Semba, T., Yasuda-Yoshihara, N., Yamada, K., Nishimura, A., Yamasaki, J., Nagano, O., Yasuda, T., Yonemura, A., Tong, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163022 · Cited by 121
“Consistent with our findings, prostate 366 cancer cell-derived lactate can be taken up by the myofibroblast line WPMY-1 367 via the TCA cycle(49).”
MethodZhao, J., Jin, D., Huang, M., Ji, J., Xu, X., Wang, F., Zhou, L., Bao, B., Jiang, F., Xu, W., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1416472 · Cited by 84
Metadata
- Authors
- Linares, J. F., Cid-Diaz, T., Duran, A., Osrodek, M., Martinez-Ordoñez, A., Reina-Campos, M., Kuo, H.-H., Elemento, O., Martin, M. L., Cordes, T., Thompson, T. C., Metallo, C. M., Moscat, J., & Diaz-Meco, M. T.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 39
- Issue
- 6
- Pages
- 110792
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W4280560497
- Cited by
- 76
- References
- 14
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. https://app.cochat.ai/papers/10.1016/j.celrep.2022.110792
- The paper
- Linares, J. F., Cid-Diaz, T., Duran, A., Osrodek, M., Martinez-Ordoñez, A., Reina-Campos, M., Kuo, H.-H., Elemento, O., Martin, M. L., Cordes, T., Thompson, T. C., Metallo, C. M., Moscat, J., & Diaz-Meco, M. T. (2022). The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Reports. https://doi.org/10.1016/j.celrep.2022.110792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.